Immix Biopharma Inc
IMMX5.810USD
+0.090+1.57%
收盘 12/22, 16:00（美东）报价延迟15分钟
191.94M总市值
亏损市盈率 TTM
关于 Immix Biopharma Inc 公司
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
Immix Biopharma Inc简介
公司代码IMMX
公司名称Immix Biopharma Inc
上市日期Dec 16, 2021
CEORachman (Ilya)
员工数量18
证券类型Ordinary Share
年结日Dec 16
公司地址11400 West Olympic Blvd.
城市LOS ANGELES
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编90064
电话18889581084
网址https://immixbio.com/
公司代码IMMX
上市日期Dec 16, 2021
CEORachman (Ilya)
Immix Biopharma Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.86M
--
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
421.94K
--
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
174.75K
-0.13%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
173.19K
+161.79%
Mr. Gabriel Morris
Mr. Gabriel Morris
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Graham Ross
Dr. Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Acting Chief Medical Officer, Head - Clinical Development
--
--
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Dr. Ilya Rachman, M.D., Ph.D.
Dr. Ilya Rachman, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Carey Ng, Ph.D.
Mr. Carey Ng, Ph.D.
Independent Director
Independent Director
--
--
Dr. Vladimir Torchilin, Ph.D.
Dr. Vladimir Torchilin, Ph.D.
Scientific Co-Founder
Scientific Co-Founder
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.86M
--
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
421.94K
--
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
174.75K
-0.13%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
173.19K
+161.79%
Mr. Gabriel Morris
Mr. Gabriel Morris
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Graham Ross
Dr. Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Acting Chief Medical Officer, Head - Clinical Development
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Hsu (Jason)
9.32%
GKCC, LLC
6.21%
Rachman (Ilya M)
2.19%
Ng (Carey)
2.00%
Bleichroeder LP
1.63%
其他
78.65%
持股股东
持股股东
占比
Hsu (Jason)
9.32%
GKCC, LLC
6.21%
Rachman (Ilya M)
2.19%
Ng (Carey)
2.00%
Bleichroeder LP
1.63%
其他
78.65%
股东类型
持股股东
占比
Individual Investor
16.15%
Corporation
6.21%
Investment Advisor
4.09%
Investment Advisor/Hedge Fund
1.78%
Hedge Fund
0.21%
Venture Capital
0.07%
Research Firm
0.07%
其他
71.42%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
60
2.79M
8.55%
-1.92M
2025Q2
65
14.67M
52.67%
-1.12M
2025Q1
66
14.50M
53.34%
-1.02M
2024Q4
67
14.42M
52.43%
-1.29M
2024Q3
66
15.60M
56.77%
-243.92K
2024Q2
66
15.89M
59.32%
-308.72K
2024Q1
64
15.43M
77.52%
+5.90M
2023Q4
57
11.10M
62.12%
+3.00M
2023Q3
52
12.47M
73.23%
+2.63M
2023Q2
46
9.35M
66.71%
-203.85K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Hsu (Jason)
4.86M
14.87%
--
--
Apr 22, 2025
GKCC, LLC
3.24M
9.92%
--
--
Apr 22, 2025
Rachman (Ilya M)
1.14M
3.49%
+2.50K
+0.22%
Sep 17, 2025
Ng (Carey)
1.05M
3.2%
--
--
Apr 22, 2025
Bleichroeder LP
850.00K
2.6%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
698.54K
2.14%
--
--
Jun 30, 2025
Chang (Nancy T)
421.94K
1.29%
+421.94K
--
Sep 08, 2025
Morris (Gabriel S)
585.64K
1.79%
+2.60K
+0.45%
Sep 16, 2025
Lynwood Capital Management Inc.
405.00K
1.24%
+405.00K
--
Mar 31, 2024
Geode Capital Management, L.L.C.
161.12K
0.49%
+373.00
+0.23%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
占比0.01%
Dimensional US Core Equity 1 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Immix Biopharma Inc的前五大股东是谁？
Immix Biopharma Inc 的前五大股东如下：
Hsu (Jason)持有股份：4.86M，占总股份比例：14.87%。
GKCC, LLC持有股份：3.24M，占总股份比例：9.92%。
Rachman (Ilya M)持有股份：1.14M，占总股份比例：3.49%。
Ng (Carey)持有股份：1.05M，占总股份比例：3.20%。
Bleichroeder LP持有股份：850.00K，占总股份比例：2.60%。
Hsu (Jason)持有股份：4.86M，占总股份比例：14.87%。
GKCC, LLC持有股份：3.24M，占总股份比例：9.92%。
Rachman (Ilya M)持有股份：1.14M，占总股份比例：3.49%。
Ng (Carey)持有股份：1.05M，占总股份比例：3.20%。
Bleichroeder LP持有股份：850.00K，占总股份比例：2.60%。
Immix Biopharma Inc的前三大股东类型是什么？
Immix Biopharma Inc 的前三大股东类型分别是：
Hsu (Jason)
GKCC, LLC
Rachman (Ilya M)
Hsu (Jason)
GKCC, LLC
Rachman (Ilya M)
有多少机构持有Immix Biopharma Inc(IMMX)的股份？
截至2025Q3，共有60家机构持有Immix Biopharma Inc的股份，合计持有的股份价值约为2.79M，占公司总股份的8.55%。与2025Q2相比，机构持股有所增加，增幅为-44.11%。
哪个业务部门对Immix Biopharma Inc的收入贡献最大？
在--，--业务部门对Immix Biopharma Inc的收入贡献最大，创收--，占总收入的--%。
